WO2006129867A3 - ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN - Google Patents

ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN Download PDF

Info

Publication number
WO2006129867A3
WO2006129867A3 PCT/JP2006/311371 JP2006311371W WO2006129867A3 WO 2006129867 A3 WO2006129867 A3 WO 2006129867A3 JP 2006311371 W JP2006311371 W JP 2006311371W WO 2006129867 A3 WO2006129867 A3 WO 2006129867A3
Authority
WO
WIPO (PCT)
Prior art keywords
lacritin
lactoferrin
compound
enhanced expression
activity
Prior art date
Application number
PCT/JP2006/311371
Other languages
French (fr)
Other versions
WO2006129867A2 (en
Inventor
Yoshiyuki Tamada
Mitsuyoshi Azuma
Original Assignee
Senju Pharma Co
Yoshiyuki Tamada
Mitsuyoshi Azuma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Yoshiyuki Tamada, Mitsuyoshi Azuma filed Critical Senju Pharma Co
Publication of WO2006129867A2 publication Critical patent/WO2006129867A2/en
Publication of WO2006129867A3 publication Critical patent/WO2006129867A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a prophylactic/therapeutic agent for ocular disease and various means that enable the development thereof. Specifically, the present invention provides a screening method for a compound having lacritin activity using a lacritin receptor expression cell; an agent of inducing lactoferrin, comprising a lacritin receptor expression cell; an agent of promoting lactoferrin secretion, comprising lacritin or a compound having lacritin activity; a method of promoting lactoferrin secretion using lacritin or a compound having lacritin activity; a method of identifying or producing a lacritin receptor expression cell; and the like.
PCT/JP2006/311371 2005-06-01 2006-05-31 ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN WO2006129867A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68588405P 2005-06-01 2005-06-01
US60/685,884 2005-06-01

Publications (2)

Publication Number Publication Date
WO2006129867A2 WO2006129867A2 (en) 2006-12-07
WO2006129867A3 true WO2006129867A3 (en) 2007-04-12

Family

ID=37103311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/311371 WO2006129867A2 (en) 2005-06-01 2006-05-31 ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN

Country Status (1)

Country Link
WO (1) WO2006129867A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058383A2 (en) * 2005-11-17 2007-05-24 Senju Pharmaceutical Co., Ltd. Lipid secretion promoter containing lacritin or compound having lacritin activity
JPWO2008105454A1 (en) * 2007-02-28 2010-06-03 千寿製薬株式会社 High expression cell of lacritin
FR2948021A1 (en) 2009-07-16 2011-01-21 Oreal COSMETIC USE OF LACRITIN-TYPE POLYPEPTIDES
CN104833782B (en) * 2015-05-08 2016-07-06 中国农业科学院兰州畜牧与兽药研究所 A kind of in-vitro screening and the method detecting anti-cow endometritis medicine
KR102337935B1 (en) * 2019-04-18 2021-12-10 코스맥스 주식회사 Cosmetic composition for improving of skin barrier and moisturizing comprising lacritin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US20040081984A1 (en) * 2001-02-20 2004-04-29 Laurie Gordon W. Ocular tear growth factor-like protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US20040081984A1 (en) * 2001-02-20 2004-04-29 Laurie Gordon W. Ocular tear growth factor-like protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUJIHARA T. ET AL.: "Lactoferrin suppresses loss of corneal epithelial integrity in a rabbit short-term dry eye model.", J. OCULAR PHARMACOL. THER., vol. 14, no. 2, 1998, pages 99 - 107, XP009074064 *
SANTAGATI M.G. ET AL.: "Lactoferrin expression by bovine ocular surface epithelia: a primary cell culture model to study lactoferrin gene promoter activity.", OPHTHALMIC RES., vol. 37, 2005, pages 270 - 278, XP009074069 *
WALTON S.C. ET AL.: "Functional analysis of lacritin : secretion modulation, cell proliferation, calcium signaling and tyrosine phosphorylation.", IOVS, vol. 42, no. 4, 15 March 2001 (2001-03-15), pages S712, XP009074066 *
ZHOU L. ET AL.: "Characterisation of human tear proteins using high-resolution mass spectrometry.", ANN. ACAD. MED. SINGAPORE, vol. 35, June 2006 (2006-06-01), pages 400 - 407, XP009074070 *

Also Published As

Publication number Publication date
WO2006129867A2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
WO2007073497A3 (en) Calcium channel antagonists
SI1729753T1 (en) Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
TW200738270A (en) Method of treating depression using a TNFα antibody
WO2006105448A3 (en) Proliferation of muc1 expressing cells
WO2005072223A3 (en) Engineered proteins, and methods of making and using
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
BRPI0517091A (en) and method for treating a disease or condition by altering an opioid receptor-mediated response
PL1740156T3 (en) Method for the production of an abuse-proof, solid form of administration
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006031787A3 (en) Low-obscuration image transmitting particulate ocular therapeutic formulations
WO2006045476A3 (en) Gpr17 modulators, method of screening and uses thereof
WO2006129867A3 (en) ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN
WO2006060542A3 (en) Formulations of substituted benzoxazoles
EG25401A (en) Process for the preparation of urea.
WO2007101063A3 (en) Treatment of development-related disorders
GB0406635D0 (en) Process for the preparation of an emulsion
GB0407566D0 (en) Method for the adjustment of spherical aberration
EP1771709A4 (en) Curved panel for acoustical shell, method of manufacturing the same, and acoustical shell using the same
WO2006094134A3 (en) Kim-1 antibodies for treatment of th2-mediated conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06747207

Country of ref document: EP

Kind code of ref document: A2